
$6.000
-0.827 (-13.79%)收盤時
- 最高
- 6.854
- 開盤
- 6.790
- 成交量加權均價
- 6.28
- 成交量
- 1.49M
- 市值
- —
- 最低
- 6.000
- 成交金額
- 9.37M
- 企業價值/稅息折舊攤銷前利潤(TTM)
- 0.00
Greenland Mines Ltd, formerly Klotho Neurosciences, Inc., is a natural resources company. The Company is focused is focused on the exploration and development of the Skaergaard Project. It operates with two operating divisions Natural Resources and Cell and Gene Therapy. The Natural Resources division is focused on the exploration and development of the Skaergaard Project in Southeast Greenland, which is undeveloped palladium, gold, and platinum deposits. It operates three Mineral Exploration Licenses (MEL): MEL 2007-01, MEL 2012-25, and MEL 2021-10. The Company holds, through its acquisition of Greenland Mines Corp., an 80% interest in, and option to acquire the remaining 20% of, the Skaergaard Project. The Cell and Gene Therapy division includes the Company's KLTO-202 primary indication for amyotrophic lateral sclerosis (ALS or Lou Gehrig’s Disease).
AI 分析 of Greenland Mines Ltd (GRML)
買進Greenland Mines Ltd (GRML) is a good buy right now due to its recent 5-day price increase of 16.05% and a significant funding boost of over $42 million for its rare-earth project, indicating strong investor confidence. However, the stock has a high debt-to-equity ratio of 0.51%, which poses a risk to its financial stability.
估值指標
事件時間軸
資訊
7.510-14NewsfilterGreenland Mines Applauds Trump's Mineral Exploration Plans
8.510-14stocktwitsTrump Promotes Resource Development in Greenland
8.510-12NewsfilterGreenland Mines Welcomes EU Strategic Project Selection
8.509-26stocktwitsUS-Denmark-Greenland Military Pact Boosts Mining Stocks
7.509-25NASDAQ.COMSRX Global Updates on Investment Liquidation and New Acquisition
GRML 常見問題 —— 由 Alphio AI 解答
Greenland Mines Ltd, formerly Klotho Neurosciences, Inc., is a natural resources company. The Company is focused is focused on the exploration and development of the Skaergaard Project. It operates with two operating divisions Natural Resources and Cell and Gene Therapy. The Natural Resources division is focused on the exploration and development of the Skaergaard Project in Southeast Greenland, which is undeveloped palladium, gold, and platinum deposits. It operates three Mineral Exploration Licenses (MEL): MEL 2007-01, MEL 2012-25, and MEL 2021-10. The Company holds, through its acquisition of Greenland Mines Corp., an 80% interest in, and option to acquire the remaining 20% of, the Skaergaard Project. The Cell and Gene Therapy division includes the Company's KLTO-202 primary indication for amyotrophic lateral sclerosis (ALS or Lou Gehrig’s Disease). It operates in the Basic Materials sector.
Greenland Mines Ltd (GRML) is a good buy right now due to its recent 5-day price increase of 16.05% and a significant funding boost of over $42 million for its rare-earth project, indicating strong investor confidence. However, the stock has a high debt-to-equity ratio of 0.51%, which poses a risk to its financial stability.
社群
更多 ↗
本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。